News

Important news about our latest
developments in science & medicine.

Background Image

Press Releases

  • Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award from the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education

    ALS Association Golden West Chapter Honors...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Appointment of Gustavo A. Suarez Zambrano, M.D., as Vice President, Medical Affairs

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present on ALS Clinical Programs at 2019 Muscle Study Group Annual Scientific Meeting

    Company to Share Details on Collaboration...

    Read more
  • More Than 4,000 U.S. Patients with ALS Treated with RADICAVA® (edaravone) in Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Announces Nationwide Database of ALS Infusion Services to Help Patients and Caregivers Identify Local Providers

    Launch of Searchable Online Resource...

    Read more
  • Post-Hoc Analyses of ALS Treatment Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

    Strategic Inclusion Criteria Enabled...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Names of Teens And Young Adults Chosen for Inclusion In ALSO US™ Initiative

    Program Fosters Use of Original Written...

    Read more
  • Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients in the U.S. Have Been Treated With RADICAVA® (edaravone)

    Over 1,000 U.S. HCPs Have Prescribed...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS

    Findings Will Help Further Understanding...

    Read more
  • Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA

    Initial Study Results Show A Single Oral...

    Read more
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA® (Edaravone) in the Last Year

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years

    Since Becoming Available, More Than 2,500...

    Read more
  • Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting

    Analysis of Patient U.S. Health Claims...

    Read more
  • Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone)

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available

    Searchlight SupportTM Staff...

    Read more
  • Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • First FDA-approved Treatment for ALS in 22 Years Now Available in U.S.

    RADICAVATM (edaravone)...

    Read more
  • MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVATM (Edaravone)

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVATM (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • MT Pharma America Announces FDA Approval of RADICAVATM (Edaravone), the First New Treatment Option for ALS in More Than 20 Years

    First FDA-approved ALS treatment option in...

    Read more
  • 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND

    Mitsubishi Tanabe Pharma Corporation (Head...

    Read more
  • FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS

    Edaravone may be the first ALS treatment...

    Read more
  • Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting

    Mitsubishi Tanabe Pharma Corporation...

    Read more
  • First Patient Enrolled in MTPA REFINE-ALS Biomarker Study

    Study is Company’s First Clinical...

    Read more
  • Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient- Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson’s Disease and Movement Disorders

    Investigational Treatment with ND0612...

    Read more
  • Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated in the United States for Parkinson’s Disease

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Presents at 2019 National ALS Registry Annual Meeting in Atlanta

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Oxford Biodynamics Joins ALS Biomarker Study Sponsored by Mitsubishi Tanabe Pharma America

    Proprietary Technology Platform to Assess...

    Read more
  • Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference

    Poster Presentations Include Real-World...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Collaboration with Massachusetts General Hospital on ALS Biomarker Study

    Findings May Help Advance Understanding of...

    Read more
  • Mitsubishi Tanabe Pharma America Accepting Independent Research Program Submissions for RADICAVA® (edaravone) Through March 8

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Launches National Online Directory of ALS Specialists and Neurologists at Multidisciplinary Centers

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow

    Presentations Highlight Commitment to...

    Read more
  • Mitsubishi Tanabe Pharma America’s ALSO USTM Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS

    Program to Showcase Original, Teen-Created...

    Read more
  • Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on Radicava® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    Assessments of RADICAVA Clinical Trial...

    Read more
  • Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting

    Phase 2 Data on Investigational...

    Read more
  • Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review

    Mitsubishi Tanabe Pharma Canada Launched...

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Perspective Regarding Medicare Coverage

    As an FDA-approved therapy, RADICAVATM...

    Read more
  • MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients

    MT Pharma America, Inc. today announced...

    Read more
  • RADICAVATM (edaravone) Prescribing Information

    ...

    Read more
  • MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • The ALS Association Welcomes MT Pharma America as National Corporate Sponsor

    The ALS Association is pleased to announce...

    Read more
  • Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States

    Mitsubishi Tanabe Pharma Corporation...

    Read more
  • Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award from the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education

    ALS Association Golden West Chapter Honors...

    Read more
  • First Patient Enrolled in MTPA REFINE-ALS Biomarker Study

    Study is Company’s First Clinical...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Appointment of Gustavo A. Suarez Zambrano, M.D., as Vice President, Medical Affairs

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient- Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson’s Disease and Movement Disorders

    Investigational Treatment with ND0612...

    Read more
  • Mitsubishi Tanabe Pharma America to Present on ALS Clinical Programs at 2019 Muscle Study Group Annual Scientific Meeting

    Company to Share Details on Collaboration...

    Read more
  • Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated in the United States for Parkinson’s Disease

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • More Than 4,000 U.S. Patients with ALS Treated with RADICAVA® (edaravone) in Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Presents at 2019 National ALS Registry Annual Meeting in Atlanta

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Announces Nationwide Database of ALS Infusion Services to Help Patients and Caregivers Identify Local Providers

    Launch of Searchable Online Resource...

    Read more
  • Oxford Biodynamics Joins ALS Biomarker Study Sponsored by Mitsubishi Tanabe Pharma America

    Proprietary Technology Platform to Assess...

    Read more
  • Post-Hoc Analyses of ALS Treatment Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

    Strategic Inclusion Criteria Enabled...

    Read more
  • Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference

    Poster Presentations Include Real-World...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Names of Teens And Young Adults Chosen for Inclusion In ALSO US™ Initiative

    Program Fosters Use of Original Written...

    Read more
  • Mitsubishi Tanabe Pharma America Announces Collaboration with Massachusetts General Hospital on ALS Biomarker Study

    Findings May Help Advance Understanding of...

    Read more
  • Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Accepting Independent Research Program Submissions for RADICAVA® (edaravone) Through March 8

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients in the U.S. Have Been Treated With RADICAVA® (edaravone)

    Over 1,000 U.S. HCPs Have Prescribed...

    Read more
  • MTPA Launches National Online Directory of ALS Specialists and Neurologists at Multidisciplinary Centers

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS

    Findings Will Help Further Understanding...

    Read more
  • Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow

    Presentations Highlight Commitment to...

    Read more
  • Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA

    Initial Study Results Show A Single Oral...

    Read more
  • Mitsubishi Tanabe Pharma America’s ALSO USTM Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS

    Program to Showcase Original, Teen-Created...

    Read more
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA® (Edaravone) in the Last Year

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on Radicava® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    Assessments of RADICAVA Clinical Trial...

    Read more
  • Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years

    Since Becoming Available, More Than 2,500...

    Read more
  • Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting

    Phase 2 Data on Investigational...

    Read more
  • Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting

    Analysis of Patient U.S. Health Claims...

    Read more
  • Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review

    Mitsubishi Tanabe Pharma Canada Launched...

    Read more
  • Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone)

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available

    Searchlight SupportTM Staff...

    Read more
  • Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services

    Mitsubishi Tanabe Pharma America, Inc....

    Read more
  • MTPA Perspective Regarding Medicare Coverage

    As an FDA-approved therapy, RADICAVATM...

    Read more
  • First FDA-approved Treatment for ALS in 22 Years Now Available in U.S.

    RADICAVATM (edaravone)...

    Read more
  • MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America

    MT Pharma America, Inc. today announced...

    Read more
  • MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVATM (Edaravone)

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients

    MT Pharma America, Inc. today announced...

    Read more
  • Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVATM (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • RADICAVATM (edaravone) Prescribing Information

    ...

    Read more
  • MT Pharma America Announces FDA Approval of RADICAVATM (Edaravone), the First New Treatment Option for ALS in More Than 20 Years

    First FDA-approved ALS treatment option in...

    Read more
  • MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting

    MT Pharma America, Inc. (MTPA) today...

    Read more
  • 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND

    Mitsubishi Tanabe Pharma Corporation (Head...

    Read more
  • The ALS Association Welcomes MT Pharma America as National Corporate Sponsor

    The ALS Association is pleased to announce...

    Read more
  • FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS

    Edaravone may be the first ALS treatment...

    Read more
  • Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States

    Mitsubishi Tanabe Pharma Corporation...

    Read more
  • Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting

    Mitsubishi Tanabe Pharma Corporation...

    Read more

Load More

Scientific Exchange

  • May
    American Academy of Neurology (AAN) Annual Meeting
    May 4-10 in Philadelphia, PA
  • Apr
    Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
    April 13-17 in Orlando, FL
  • Dec
    MNDA Motor Neuron Disease Association Symposium
    December 6 – 9 in Glasgow, Scotland